AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (5.3 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese

Role and mechanism of PSMA4 in prognosis, diagnosis and immune infiltration of lung adenocarcinoma

Jing ZHAO1Yanmei LI2Xueyue WANG3Tian NIE4Jie WANG1Qiming WENG1Jing ZHANG5( )Ye FAN6( )
Training Center for Clinical Skills, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037
Department of Clinical Laboratory, General Hospital of Western Theater Command, Chengdu, Sichuan Province, 610083
Department of Pediatrics, General Hospital of Xizang Command, Lasha, Xizang Autonomous Region, 850000
Digestive Endoscopy Center, Sichuan Provincial People's Hospital, Chengdu, Sichuan Province, 610072, China
Institute of Field Internal Medicine, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037
Department of Respiratory Diseases, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037
Show Author Information

Abstract

Objective

To investigate the role of PSMA4 in the prognosis, diagnosis and immune infiltration of lung adenocarcinoma (LUAD), and explore its underlying mechanism.

Methods

The expression profiles and clinical data of LUAD patients were sourced from the Cancer Genome Atlas (TCGA) database. The expression level of PSMA4 in LUAD tissues (n=539) and normal tissues (n=59) were compared using the Wilcoxon rank-sum test. The expression levels of PSMA4 in LUAD tissues and normal tissues were validated by analyzing the GSE40791 and GSE10072 LUAD datasets obtained from the Gene Expression Omnibus (GEO) database. In addition, tumor and adjacent non-cancerous tissues were collected from 10 LUAD undergoing lung biopsy by fiberoptic bronchoscopy in Second Affiliated Hospital of Army Medical University from January to December 2023. The PSMA4 expression in above samples was further verified using RT-qPCR. RT-qPCR was performed to detect the expression of PSMA4 in lung cancer cells and normal lung epithelial cells. Functional enrichment analysis and immune cell infiltration analysis were conducted on the cells with high and low expression of PSMA4. Cox regression analysis and Kaplan-Meier (KM) survival analysis were used to determine the diagnostic and prognostic value of PSMA4 for LUAD, and a nomogram was constructed to predict the overall survival rate at different time points.

Results

The analysis of TCGA datasets, GSE40791, and GSE10072 LUAD data revealed that PSMA4 expression was significantly higher in LUAD tissues than in normal tissues (P<0.01). RT-qPCR further confirmed that the expression of PSMA4 was obviously elevated in LUAD tissues and lung cancer cells than adjacent non-cancerous tissues and normal lung epithelial cells (P<0.01). High PSMA4 expression could be regarded as a marker for LUAD diagnosis and poor prognosis, and was associated with reduced proportions of Tem cells, TFH cells, B cells, NK cells, Tcm cells, and mast cells in the tumor microenvironment.

Conclusion

PSMA4 presents significant diagnostic performance for LUAD, and is closely associated with the prognosis and immune infiltration of this malignancy.

CLC number: R394.3;R730.23;R734.2 Document code: A

References

【1】
【1】
 
 
Journal of Army Medical University
Pages 1985-1993

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
ZHAO J, LI Y, WANG X, et al. Role and mechanism of PSMA4 in prognosis, diagnosis and immune infiltration of lung adenocarcinoma. Journal of Army Medical University, 2024, 46(17): 1985-1993. https://doi.org/10.16016/j.2097-0927.202405037

930

Views

13

Downloads

0

Crossref

0

Scopus

0

CSCD

Received: 13 May 2024
Revised: 29 June 2024
Published: 15 September 2024
© 2024 Journal of Army Medical University